| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Truist Securities analyst Richard Newitter maintains Integra Lifesciences (NASDAQ:IART) with a Hold and raises the price tar...
- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, is pleased to announce ...
Integra Lifesciences (NASDAQ:IART) affirms FY2025 Adj EPS guidance from $2.19-$2.29 to $2.19-$2.29 vs $2.24 analyst estimate. N...
Integra Lifesciences (NASDAQ:IART) is looking for Q3 Adj EPS of $0.40-$0.45 vs $0.58 analyst estimate. sees sales of $410.000 m...
Integra Lifesciences (NASDAQ:IART) reported quarterly earnings of $0.45 per share which beat the analyst consensus estimate of ...
https://www.fda.gov/medical-devices/medical-device-recalls/applicator-recall-integra-lifesciences-removes-micromyst-applicators...
https://www.fda.gov/medical-devices/medical-device-recalls/cranial-drill-recall-integra-lifesciences-recalls-codman-disposable-...